Results 31 to 40 of about 9,340 (184)

Mepolizumab.

Australian prescriber
  +14 more sources

Successful and safe treatment of severe steroid depended eosinophilic asthma with mepolizumab in a woman during pregnancy

Respiratory Medicine Case Reports, 2023
A 26-year-old female with steroid dependent eosinophilic asthma and nasal polyps who had successfully been treated with mepolizumab for 17 consecutive months with complete steroid withdrawal and symptoms control, stopped biologic treatment due to ...
Stylianos K. Vittorakis, Georgia Giannakopoulou, Konstantinos Samitas, Eleftherios Zervas   +3 more
doaj   +1 more source

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Journal of Allergy and Clinical Immunology: Global
Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids.
Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD   +14 more
doaj   +1 more source

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial

Allergy, Asthma & Clinical Immunology, 2019
Limited information is available on the clinical course of patients with severe asthma following discontinuation of biologic treatment. Therefore, a post hoc analysis was conducted in patients with severe eosinophilic asthma who participated in the ...
Hector Ortega, Catherine Lemiere, Jean-Pierre Llanos, Mark Forshag, Robert Price, Frank Albers, Steven Yancey, Mario Castro   +7 more
doaj   +1 more source

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

Frontiers in Pharmacology, 2023
Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps.
Fan Zou, Chengyu Zhu, Siyu Lou, Zhiwei Cui, Dan Wang, Yingyong Ou, Li Wang, Junyou Chen, Yuanbo Lan   +8 more
doaj   +1 more source

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis

BMC Pulmonary Medicine, 2019
Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance ...
Takanori Numata, Katsutoshi Nakayama, Hirofumi Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano   +10 more
doaj   +1 more source

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine, 2023
BackgroundHypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage.
Florence Roufosse, Joseph Butterfield, Jonathan Steinfeld, Jane H. Bentley, Robyn von Maltzahn, Namhee Kwon, Linda Nelsen   +6 more
doaj   +1 more source

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

Frontiers in Immunology, 2022
BackgroundCurrent standard-of-care treatments for hypereosinophilic syndrome (HES) include oral corticosteroids (OCS) and immunosuppressive/cytotoxic (IS/CT) therapies.
Andreas Reiter, Guillaume Lefevre, Maria C. Cid, Namhee Kwon, Eleni Mavropolou, Steven W. Yancey, Jonathan Steinfeld   +6 more
doaj   +1 more source

Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

Allergy. European Journal of Allergy and Clinical Immunology, 2023
Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission.
D. Thomas, V. McDonald, S. Stevens, E. Harvey, M. Baraket, Philip Bardin, J. Bowden, S. Bowler, Jimmy Chien, L. Chung, A. Gillman, M. Hew, S. Hodge, Alan James, C. Jenkins, C. Katelaris, G. Katsoulotos, D. Langton, Joy Lee, G. Marks, M. Peters, N. Radhakrishna, P. Reynolds, J. Rimmer, P. Sivakumaran, J. Upham, P. Wark, I. Yang, P. Gibson   +28 more
semanticscholar   +1 more source

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source